Dopamine receptor agonists are the main therapy class that mimics dopamine function in PD patients ^[23][24]. All the dopamine receptors are G protein-coupled receptors containing D₁ and D₂ types; they pair with Gs of G proteins, which trigger the adenylyl cyclase system and consequently rouse the cAMP synthesis ^[25]. D₁ receptor contains D₁ and D₅ subtypes; D₂ receptor contains D₂, D₃, and D₄ subtypes ^[26][27]. Although upon the prolonged oral dopamine receptor agonists, treatment becomes unresponsive ^[16][28].

We found six clinical trials that used four small molecular drugs that act as a dopamine receptor agonist in PD treatment. PF-06412562 is a moderately potent, highly selective oral D₁/D₅ dopamine receptor partial agonist; PF-06412562 has good selectivity than other dopamine receptor subtypes ^[29]. In a phase I trial, oral administration PF-06412562 had potential antiparkinsonian efficacy in 13 PD patients without significant acute changes in cardiovascular parameters reported with previous D₁ agonists (Table 1) (NCT03665454) ^[29]. The trial results revealed that the PF-06412562 was well tolerated in advanced PD patients and met the primary and secondary endpoints ^[30]. PF-06669571 is a novel and oral D₁/D₅ dopamine receptor partial agonist with a non-catechol-based structure that has demonstrated efficacy in preclinical models of PD symptoms ^[31]. Gurrell et al. (2018) showed that PF-06669571 (1 or 3 mg, four times a day) in the phase I trial was safe and well-tolerated with minor adverse events such as nausea in 10 idiopathic PD patients (Table 1) (NCT02565628) ^[31]. PF-06649751 is also a novel, oral, non-catechol, D₁/D₅ dopamine receptor partial agonist ^[32]. In phase I study, PF-06649751 showed safety, efficacy, and tolerability with pharmacological profile; further phases of trials on a larger scale were carryout by Pfizer (Table 1) (NCT02224664) ^[32]. In addition, the phase II study PF-06649751 (1 daily oral dose) demonstrated significant motor balance improvement and was well-tolerated in 25 early-stage PD patients (NCT02847650) ^[33]. The study showed PF-06649751 treatment had the most common adverse events, including nausea, headache, dry mouth, somnolence, and tremor ^[33]. The phase II trials of PF-06649751 failed to demonstrate efficacy in moderate/advanced PD and were terminated (Table 1) (NCT02847650 and NCT02687542). The D₂-specific dopamine receptor agonist CJH1 (CLR4001) is undergoing a phase I/II clinical trial developed by Alexandra Marine and General Hospital, and the current trial status has not been updated since 2012 (Table 1) (NCT01684475). Moreover, the clinical data of PF-06412562 ((4-[4-(4,6-dimethyl-5-pyrimidinyl)-3-methylphenoxyl]-1H-pyrazolo [4,3-c]pyridine) showed safety and tolerability against advanced PD (NCT03665454) ^[30]. The PF-06669571 treatment was also reported as safe and tolerable against idiopathic PD ^[31]. Among the three trials of PF-06649751, two (NCT02847650 and NCT02687542) were discontinued due to insufficient efficacy, and one trial shows phase I, but no post updated since March 2017 (NCT02224664).

Long-term (1–5 years) usage of dopamine receptor agonists offers adverse effects based on the dosage. The side effects include nausea, vomiting, irregular heartbeats, low blood pressure, renal/pulmonary diseases, and dizziness ^[4034]. Besides, extended dopamine receptor agonist usage causes chorea/dystonic movements, illusions, delusions, mania, mental disturbances, yawning, and irresistible sleep periods ^[4034]. Several studies revealed that dopamine receptor agonists aid in drug-induced mental illness, anxiety, anorexia nervosa, schizophrenia, hypersexuality, gambling mentality, and compulsive shopping disorders ^[4135]. Among currently used dopamine receptor agonists for PD treatment, pramipexole treatment might have maximum side effects ^[4236].

α-Synuclein, an unfolded highly soluble protein in presynaptic neurons of the brain ^[4337]. α-Synuclein aggregation is a pathologic hallmark of synucleinopathies in sporadic and hereditary PD ^[4438]. Aggregation of α-synuclein induces many pathological conditions such as autophagy or lysosomal disorder, synaptic dysfunction, mitochondrial dysfunction, endoplasmic reticulum stress, and oxidative stress ^[4539][4640]. All the pathological conditions further lead to proteinaceous cytoplasmic inclusions, known as Lewy bodies and Lewy neurites ^[4640]. Anti-α-synuclein aggregation treatment mainly increases the cellular clearance mechanisms and regulates Lewy bodies ^[4741].

In anti-α-synuclein aggregation therapies, we found five clinical trials that use monoclonal antibodies (ABVV-0805, BIIB054, and PRX002) or vaccines (AFFITOPE^® PD01A), and two trials use small molecules (ambroxol and Cu(II)ATSM) in the clinical trials for PD. In a phase I trial, monoclonal antibody ABVV-0805 has been withdrawn due to strategic considerations by AbbVie (Table 2) (NCT04127695). BIIB054 (cinpanemab) is an IgG₁ protein produced from memory B cells from aged people without nervous system diseases ^[4842]. BIIB054 treatment showed an 800-fold higher affinity towards binding to α-synuclein that inhibited spread or aggregation and improved motor balances ^[4842]. The current status of the BIIB054 (phase II) study shows termination due to not meeting the primary and secondary endpoints for the treatment of PD (Table 2) (NCT03318523).

Anti-α-synuclein monoclonal antibody PRX002 (RO7046015/prasinezumab) is developing (phase II) by Hoffmann-La Roche (NCT03100149). In addition, a phase-I study used PRX002 that targets anti-α-synuclein is developing by Prothena Bio-sciences Limited (Table 2) (NCT02157714). Jankovic et al. (2018) showed that single and multiple doses of the anti-α-synuclein monoclonal antibody PRX002 were generally safe and well-tolerated, and it resulted in robust binding of peripheral α-synuclein and dose-dependent increases of PRX002 in cerebrospinal fluid (Table 2) (NCT03100149) ^[5043]. AFFITOPE^® PD01A is a phase I experimental vaccine made by short synthetic peptides to produce antibodies against α-synuclein aggregation and improve immunity, developed by Affiris AG (Table 2) (NCT01568099) ^[5744]. The same vaccine AFFITOPE^® PD01A trials were also registered with NCT01885494, NCT02216188, and NCT02618941 by Affiris AG (Table 2) ^[5744]. AFFITOPE^® PD01A demonstrated safe and well-tolerated in patients; the trials also showed increased antibodies in the blood and cerebrospinal fluid extended by Affiris AG for further studies ^[5744][4945]. Ambroxol is a potential disease-modifying small molecule that targets α-synuclein aggregation (Table 1). Since 1979, ambroxol has been using as a drug for cough ^[5846]. A report indicates ambroxol blocks autophagy and driving cargo towards the secretory pathway ^[5947]. To date, the ambroxol administration has not been reported for severe side effects; more or less, it may cause gastric ulceration ^[5846]. Mullin et al. (2020) showed that ambroxol therapy could cross the blood-brain barrier, dock with the enzyme β-glucocerebrosidase, and decrease cerebrospinal fluid α-synuclein level in PD patients without glucocerebrosidase genetic mutations ^[6048]. The preclinical data of ambroxol reduced α-synuclein aggregation and lowered the disease progression ^[6048][3449]. The Lawson Health Research Institute is developing ambroxol as an anti-PD drug. The current status is under subject recruitment at phase II without result, and the study is estimated to be completed by December 2021 (NCT02914366). Next, Copper (II) diacetylbis (N(4)-methyl thio semi carbazonato) (Cu(II)ATSM) is a small molecule permeable to the blood-brain barrier, which is currently in a phase I trial for PD treatment developing by Collaborative Medicinal Development Pty Limited. Cu(II)ATSM treatment improves neuroprotection by cognitive and motor performances via modulating brain metal levels and dopamine metabolism in animal models ^[6150]. The trial status of Cu(II)ATSM shows that subject recruiting is complete, and no published data are available (Table 1) (NCT03204929).

Recent literature shows that the use of small molecules against α-synuclein aggregation is safe and efficient by increasing autophagy/lysosomal flux than other PD therapies ^[4640], for instance, ambroxol or Cu(II)ATSM small molecule α-synuclein target drugs being tested in the pipeline of clinical trials, and could be successful drugs in future. In PD, α-synuclein aggregates induce neuronal loss, one of the key factors associated with neuroinflammation ^[6251]. Nevertheless, the long-term usage of α-synuclein targeted therapies may also cause several side effects such as loss of synaptic functions and disruption of endoplasmic reticulum-Golgi stress ^[6352].

Plasma contains antibodies, protein complexes, salts, and organic compounds. Therefore, plasma therapy has emerged as one of the safe and well-tolerated PD treatments ^[5158]. It is well-known that infusion of the young plasma reduces α-synuclein and Lewy bodies. We found a phase I clinical trial study developing by Stanford University using the transfusion of young plasma (1 unit, twice a week for four weeks) into 15 moderate-stage PD patients (Table 2) (NCT02968433). The trial results show that young fresh frozen plasma was safe, feasible, well-tolerated in PD patients, with no serious adverse events, and the most common adverse effects were mild skin reactions during infusions ^[5158]. In addition, the data showed young plasma maintained improvements in phonemic fluency and the stigma subscore of the PDQ-39 and reduced peripheral TNF-α ^[5158].

α-Synuclein aggregation is not the only cause for PD progression; multiple factors are associated with the disease; hence plasma therapy may show limited effects ^[6459]. Nevertheless, plasma therapy also causes health risks such as allergic reactions, breathing difficulties, infection to human immunodeficiency virus (HIV), hepatitis B or hepatitis C virus, or even may cause infection with unknown viruses ^[5158][6560].

Cell therapy involves the introduction of dopamine-producing cells into the brain via transplantation. Cell-based therapy is a sustainable option that can reduce neurological inflammation in PD ^[6661]. Spheramine (BAY86-5280) is a human retinal cultured epithelial pigment that produces levodopa ^[5262]. In a phase II trial, 35 PD patients were transplanted spheramine (325,000 cells/side) into the post-commissural putamen by micro-carrier in 36 PD patients who underwent sham surgery (Table 2) (NCT00206687). The result showed spheramine did not have significant anti-parkinsonism effects (change in mean motor scores did not differ significantly between groups) ^[5262]. In this trial, 2 and 7 patients died in the sham surgery and spheramine transplantation group, respectively ^[5262]. Porcine choroid plexus produces several neurotrophins and can be safely delivered to the striatum in an encapsulated formulation to protect them from immune attack ^[6763]. NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells ^[6864]. In 2013, Living Cell technologies hosted a phase I/II trial of NTCELL implantation (Table 2). The trial status shows it was completed on 4 June 2020, and no published data are available (NCT01734733). The phase II trial results showed intra-striatal NTCELL implantation was safe and well-tolerated without change in Unified PD Rating Scale (UPDRS) motor scores for 26 weeks post-intervention compared with baseline (Table 2) (NCT02683629) ^[6763]. In cell-based therapies, embryonic dopamine cell implant surgery entered into phase III trials by the University of Colorado Denver (Table 2) (NCT00038116). The published data of the embryonic dopamine cell surgery revealed that it benefits in reversing severe PD symptoms in younger patients, but not in older patients ^{[65][66][67][68][69][70][71][72][73][74][75][76][53]}. Neuronal progenitor stem cells are collected from the adult human brain to treat PD, Alzheimer’s disease, and multiple sclerosis by Rajavithi Hospital (Thailand) (NCT00927108). Recent information on the neuronal progenitor stem cell therapy clinical trial shows withdrawn by Rajavithi Hospital for unspecific reasons (NCT00927108). In cell therapy, the spheramine, and neuronal progenitor stem cells were discontinued from phase II. NTCELL and embryonic dopamine cell implant methods showed safety and tolerability against PD and could be effective. However, cell therapies may also cause immunosuppression and genetic changes that lead to genetic overexpression or carcinoma; or the treatment may be less effective with a higher risk of non-motor expressions depending on the patient ^[7774].

Gene therapy for PD treatment includes genetically engineered therapeutic genes that actively replace, knockout, or correct the faulty genes in PD patients ^[7875]. Various serotypes of non-replicating genetically engineered viral vectors, such as an adeno-associated virus (AAV) or lentivirus, have been applied in gene therapy ^[7976]. Gene therapy can prevent dopaminergic neuronal death in the brain ^[8077]. In PD, gene therapies mainly aim to increase the stimulation of neurotrophic action in the brain to improve motor balance in patients ^[8178]. Besides, regulation of glucocerebrosidase levels by gene therapy is one potential therapeutic approach in treating PD ^[8279].

We observed six clinical trials (five gene therapies and one small molecular) that use gene therapy for PD treatment, such as AAV2-GDNF, AAV-GAD, CERE-120 (2 trials), PR001A, and GZ/SAR402671. Presently, AAV2-GDNF (adeno-associated virus serotype 2 borne glial cell line-derived neurotrophic factor) is in a non-randomized open-label safety trial developing for PD treatment by Brain Neurotherapy Bio, Inc. (Table 2). In this phase I trial, they transfer AAV2-GDNF into putamen; the trial status shows under subject recruitment, no published data available (NCT04167540). In a phase I trial, subthalamic nucleus gene transfer by the AAV-GAD (adeno-associated virus borne glutamic acid decarboxylase) indicated safe, well-tolerated, and significant improvements in motor UPDRS scores in 12 advanced PD patients (Table 2) (NCT00195143) ^[5480]. Bilateral stereotactic administration of CERE-120 (AAV2-neurturin) into the substantia nigra was safe and well-tolerated, CERE-120 is developing at phase I/II by Sangamo Therapeutics (Table 2) (NCT00985517) ^[5581]. Besides, a piece of news published about the study showed that the treatment failed to improve the patients’ difficulties compared to the sham group ^[8382]. Another phase II study of CERE-120 showed no significant difference between the treated and control groups (Table 2) (NCT00400634) ^[5683]. They also observed adverse effects upon treatment with CERE-120 in 13 patients out of 38 total patients ^[5683]. Besides, three of the patients from the CERE-120 treatment developed tumors. Overall, the study data showed no significant improvements compared to the control group ^[5683]. Gene therapy using PR001A targets glucocerebrosidase activity. Preclinical data of PR001A administration also showed diminished α-synuclein aggregation and Lewy body levels markedly ^[84]. The treatment comprises one-time administration of the GBA1 gene (encodes glucocerebrosidase) into the cisterna magna developing by Prevail Therapeutics. The current status of the PR001A phase I/IIa trial shows under subject recruitment, no data available, and is estimated to complete by June 2027 (Table 2) (NCT04127578). GZ/SAR402671 is a small molecular glucocerebrosidase gene mutating therapy in early PD, developing by Genzyme (Table 1). A phase II clinical trial assesses the safety and tolerability of oral GZ/SAR402671 for four weeks compared to placebo controls (NCT02906020). In addition, preclinical data of oral administration of GZ/SAR402671 inhibited lipid accumulation and slowed the progression of α-synuclein, ubiquitin, and tau phosphorylation, and enhanced cognitive deficits ^[3553]. GZ/SAR402671 administration was safe and well-tolerated in the phase I trial ^[3553], but the trial has been terminated due to not meeting the primary and secondary endpoints updated on 04 June 2021 (NCT02906020). Overall, the gene therapies targeting the GBA1 gene (PR001A) or neurotrophic factors (AAV-GAD) may be successful in the future.

In gene therapy, delivering the desired gene by a suitable vector into the specific brain area is a sensitive and complicated task. For instance, AAV-based vectors have a limited capacity of 4.7-kb, which prohibits the integration of multiple genes ^[85]. Several risk factors of gene therapy include impaired gait, dorsal root ganglia, ataxia, and increased transaminases ^[86][87]. In some cases, the overexpression of the transgene may cause severe toxicity to the targeted organs or tissues ^[86][87].

Motor activities, depression, cognitive and autonomic functions are regulated by the serotonergic neurotransmission system ^[88]. Therefore, drugs targeting serotonergic receptors modulate behavioral qualities and improved motor balances ^[89]. We found three clinical trials use serotonin receptor agonists (piclozotan and sarizotan) or antagonists (SYN120) for PD treatment. Piclozotan (SUN N4057) is a selective 5-HT_1A receptor agonist developing at phase II by Daiichi Sankyo, Inc. A preclinical study showed that serotonin 1A receptor agonists piclozotan ameliorate motor performances in 6-hydroxydopamine-induced models ^[90]. The trial status shows it completed subject recruitment while results show no serious adverse events compared to the placebo cohort. However, the piclozotan treatment produced few minor adverse events such as headache, nausea, dizziness, and hypertension (Table 1) (NCT00623363). Preclinical literature also showed that sarizotan benefits in reducing dyskinesia, respiratory problems ^[91]. Sarizotan possesses serotonin receptor partial agonist and dopamine D₂ receptor agonist activities, developing at phase III by EMD Sereno. The status of this trial shows no results (Table 1) (NCT00105508). A study shows that 2 mg/day sarizotan administration had no improvements in dyskinesia compared to placebo subjects ^[3654]. SYN120 is a dual 5-HT_6/5-HT₂ serotonin receptor antagonist. An update from the American Academy of Neurology’s 2019 annual meeting (on 15 May 2019) declared that the SYN120 (SYNAPSE) trial in phase II studied with 80 patients has failed to improve cognitive performance (Table 1) (NCT02258152) ^[92].

Moreover, not all the serotonin receptor agonists are active/control in mediating the PD. In addition, some of the 5-HT_2B receptor agonists reported offering adverse effects; for instance, fenfluramine, pergolide, and cabergoline were discontinued from the pharmaceutical industry due to cardiac fibrosis ^[93].

Pathogenesis of PD is associated with oxidative stress and monoamine oxidase-B activities in the glia of the brain ^[94]. Monoamine reuptake inhibitors prevent the reuptake of dopamine, serotonin, norepinephrine, and periphrastically. Together these events further activate the cholinergic system that represents potential PD therapeutic targets ^[95]. We found a clinical trial that uses a monoamine reuptake inhibitor (NS 2330) for PD treatment. NS 2330 (tesofensine) is a triple monoamine reuptake inhibitor. It inhibits the reuptake of cholinergic molecules of dopamine, serotonin, and norepinephrine. These cellular events indirectly stimulate the cholinergic system ^[96]. Presently, NS 2330 is developing at phase II by Boehringer Ingelheim. For this trial, they recruited 261 subjects with PD < 5 years that were not receiving dopaminergic treatment and randomly assigned them to daily with NS 2330 at 0.25 mg, 0.5 mg, 1.0 mg, or placebo (Table 1) (NCT00148486) ^[97]. Hauser et al.’s (2007) clinical trial data showed that NS 2330 treatment did not affect the total UPDRS score compared to placebo subjects during the fourteen-week experimental period ^[97]. Besides, the NS 2330 data were not shown to alter parkinsonian signs or dyskinesia when infused with levodopa ^[98].

Cholinergic receptors contain muscarinic receptors (sensitive to muscarine) and nicotinic receptors (sensitive to nicotinic); they function in somatic and autonomic signal transductions in the nervous system ^[99]. We observed three trials that use muscarinic or nicotinic acetylcholine receptor agonists (Table 1). ANAVEX2-73 is a small molecule that binds to muscarinic acetylcholine and sigma1 (s1) receptors in the low micromolar range developing by Anavex Life Sciences Corp ^[100]. In October 2019, they started a phase II open-label extension to evaluate the effects of ANAVEX2-73 in 120 PD subjects with dementia on the safety and efficacy of daily treatment (Table 1) (NCT04575259). Anavex Life Sciences Corp. estimates the study completion by 31 October 2021. Nicotine is used in two phase-II trials as a transdermal patch (in 2012) and a nasal spray (in 2019) for PD treatment. Unfortunately, the trial data for the nicotine transdermal patch (7 or 14 mg for 52 weeks) in PD patients is unavailable (Table 1) (NCT01560754). Another trial using nicotine nasal spray trial status shows complete under subject recruitment and no results posted (Table 1) (NCT03865121). Although the high doses of transdermal nicotine were also tolerated, they failed to show significant improvements in UPDRS scores ^[101].

Moreover, the cholinergic drug treatment disadvantages might be less efficient than dopamine receptor agonists or carbidopa-levodopa treatment or even may cause adverse effects on parasympathetic nerve-related organs in PD ^[102].

In addition to the dopaminergic neuronal loss in PD, dysregulation of NMDAR in the cortical-striatal-pallidal-thalmo-cortical network and changes in plasticity of the brain regions are also crucial for cognitive function ^[103]. NMDAR modulators enhance synaptic plasticity ^[103]. We observed two trials in phase II that use NMDA receptor modulators (NYX-458 and DAAOI-P) in the PD treatment (Table 1). NYX-458 is an NMDAR modulator that increases cognitive properties and synaptic plasticity ^[103][104]. NYX-458 phase II trial plans to recruit PD subjects with mild cognitive impairments; the trial status shows the active recruiting and is estimated to complete by 22 December 2022 (NCT04148391). DAAOI-P (Flavoenzyme) is a D-amino acid oxidase inhibitor that facilitates the NMDA receptor subunit-1 and catalyzes/degrades D-amino acids by oxidative deamination in PD dementia developing by China Medical University Hospital (Taiwan). The phase II trial status of DAAOI-P in PD subjects with dementia shows under recruitment, and no published data is available; the trial is estimated to complete by July 2022 (NCT04470037).

NMDAR modulators also showed adverse effects such as irregular heartbeats, nausea, vomiting, psychosis, catalepsy, constipation, analgesia, and amnesia ^[105][106].

During PD progression, degeneration of neurons occurs due to apoptosis and necrosis ^[19]. We observed two clinical trials that use small molecule anti-apoptotic drugs, i.e., TCH346 and minocycline. TCH346 is also known as dibenz[b,f]oxepin-10-ylmethyl-prop-2-ynyl-amine hydrogen maleate salt. TCH346 is undergoing phase I/II clinical trial in 301 early-stage PD patients, and it is developing by Novartis; the trial status shows it is complete, and no published data are available (Table 1) (NCT00407212). Preclinical data showed that TCH346 protected from dopaminergic neuronal damage ^[107]. Minocycline is a neuroprotective synthetic tetracycline derivative that mainly targets anti-apoptotic pathways; it modulates microglial cells and reduces oxidative stress and neuroinflammation ^[108]. Minocycline treatment (200 mg/day) has completed the phase II clinical trial in 66 subjects with early untreated PD patients (Table 1) (NCT00063193). The published trial data showed that the mean changes in total UPDRS scores for minocycline were not significantly different in PD treatment ^[3755].

LRRK2 kinase activities and their effects in PD enhance the degeneration of disease progression; LRRK2 inhibition offers neuroprotection in PD ^[109]. We identified two clinical trials that use small molecule kinase inhibitors (CEP-1347 and K0706). CEP-1347 (KT7515) is a semisynthetic inhibitor of the mixed lineage kinase family; it promotes neuronal survival by inhibiting c-Jun amino-terminal kinases (JNKs) activation ^[110]. CEP-1347 was in phase II/III trial and was terminated by Cephalon due to insignificant trial results (Table 1) (NCT00040404) ^[3856][111]. The published trial results showed that urate and its determinants caused the disease progression ^[3856]. Moreover, CEP-1347 treatment fails to slower disease progression in early PD patients ^[111]. K0706 is a potent orally selective inhibitor of cABL protein tyrosine kinase; K0706 exhibits neuroprotective activity ^[112]. A phase II trial using K0706 was performed by Sun pharma (SPARC) (Table 1). The trial status of K0706 in early PD subjects shows under subject recruitment with no results posted and is estimated to be completed by March 2023 (NCT03655236).

Kinase inhibitors may also cause side effects such as fatigue, diarrhea, hypertension, abnormal wound healing or rashes, periorbital edema, and myelosuppression ^[113][114].

Mitochondrial dysfunction, oxidative stress, and the formation of excessive reactive oxygen species are involved in the progress of PD neurodegeneration ^[115]. Myeloperoxidase inhibition reduces the production of reactive oxygen species and further neuroinflammation in PD ^[116]. We found a clinical trial that uses AZD3241 as a myeloperoxidase inhibitor. It is an irreversible myeloperoxidase inhibitor and was found to be safe without serious adverse events; the common side effects are nausea, headache, nasopharyngitis, insomnia, and weakness ^[115]. AZD3241 undergoes a phase II clinical trial (300 or 600 mg, two times a day for 12 weeks) in 51 PD subjects (by AstraZeneca). The trial status shows complete, and no published data is available (Table 1) (NCT01603069). Jucaite et al. (2015) showed that administration of AZD3241 (at 600 mg twice a day for eight weeks) inhibited 11C-PBR28 binding to the translocator proteins (a hallmark of microglial activation) and inflammation in the PD patients and might be effective against myeloperoxidation in PD ^[115].

Adenosine receptors are promising therapeutic targets for a variety of diseases, including PD ^[117]. We found two clinical trials that use adenosine A_2A receptor antagonists (V81444 and caffeine). The V81444 is a small molecular drug for PD treatment in phase I clinical trial, developing by Vernalis (R&D) Ltd., Kansas, United States (Table 1). The trial status shows completed in subject recruiting, and the result is unavailable (NCT02764892). Moreover, the Vernalis (R&D) patented V81444 for further trials and commercialization of the drug ^[118]. Caffeine acts as a selective adenosine A_2A receptor antagonist (due to its xanthine property) ^[119] and reduces neurotoxicity by blocking A_2A receptors ^[120]. In 2014, McGill University Health Centre performed the phase III trial of caffeine for PD treatment (Table 1) (NCT01738178). The trial result shows that caffeine did not provide clinically efficient improvement of motor manifestations in 60 PD patients ^[3957]. Based on the available data, V81444 might be an effective Adenosine A_2A antagonist compared to caffeine treatment. However, the epidemiologic links between caffeine and lower PD risk do not appear to be explained by symptomatic effects ^[3957].

The free radical scavenging activity of antioxidants is the major contributor to the protection of dopaminergic neurons and improved mitochondrial functions in sporadic and hereditary PD ^[121]. Mitochondrial dysfunction is associated with PD pathogenesis; free radical scavenging activity eliminates damaged mitochondria by mitophagy and provides neuroprotection in PD ^[122]. The decrease of reduced glutathione in the PD brain is one of the pathogenic hallmarks of neuroinflammation ^[123]. It indicates the importance of reduced glutathione therapy against the oxidation of neurons in the PD treatment. Intranasal application of reduced glutathione (tripeptide glutathione) is a new method of administration used in the antioxidant treatment. We found two clinical trials that use intranasal glutathione as antioxidant therapy for PD treatment in phase I. The status of intranasal glutathione therapy for thirty-four PD subjects shows it is complete without results (NCT01398748). In addition, the trial status of intranasal reduced glutathione therapy for 15 PD subjects also shows it is complete without trial results (NCT02324426). The reduced glutathione treatment modulates the excessive free radical formation and inhibits neuroinflammation in PD ^[124].

In herbal extract treatment, we observed two clinical trials (Win-1001X and hypoestoxide) for PD treatment. Win-1001X is a plant-based herbal extract for PD treatment in phase II, developing by Medi Help Line. Win-1001X contains the extracts of three plants, for instance, Angelica tenuissima Nakai, Dimocarpus longan (L.), and Polygala tenuifolia. Kim et al. (2014) revealed that Win-1001X increased LC3-II/I, DOR, and GATE16 autophagy-related protein expressions in the midbrain and rescued neuronal damage in rodents ^[125]. Furthermore, they showed that Win-1001X extract mainly targets autophagy and antioxidant mechanisms and reduced neuroinflammation ^[125]. This clinical trial used WIN-1001X (400, 800, and 1200 mg) to treat early PD patients (Table 2) (NCT04220762). However, the trial status of WIN-1001X therapy shows subject recruitment with no posted results (NCT04220762). Hypoestoxide is a natural active diterpene phytochemical constituent of Hypoestes rosea that acts against PD progression and cancer ^[126]. Ojo-Amaize and Cottom, (2016) revealed that hypoestoxide offers several beneficial effects in inhibiting the activity of IκB, NFκB, and other inflammatory pathways and modulate PD features ^[126]. Hypoestoxide is undergoing phase I/II clinical trial for PD by Adesola Ogunniyi, University of Ibadan (Table 2) (NCT04858074). Besides, preclinical data also showed improvements in motor symptoms and lowered disease progression of PD ^[127].

However, the advantages of herbal extract treatment include no serious adverse events and long-term benefits in disease management compared to modern medicine.

We found two phase-II clinical trials that use other types of drugs for the PD treatment, i.e., GM 608, and NLY01. GM 608 is a motoneuronotrophic endogenous embryonic neural regulatory and signaling peptide (synthetic oligopeptide) developing by Genervon Biopharmaceuticals, LLC. GM 608 has neuroprotection and regulates the development of the human nervous system ^[128]. The status of the GM 608 phase II trial shows completed in subject recruitment, but no published data is available (Table 1) (NCT01850381). NLY01 is a novel exenatide-based compound developing by Neuraly Inc. ^[129]. The NLY01 is a pegylated form of exendin-4 (exenatide), which binds to glucagon-like peptide-1 receptors (GLP-1R) and expresses in glial brain cells ^[129]. Studies of NLY01 in PD showed that NLY01 limited neuronal death decreased formation of an inflammatory cascade and neurotoxic astrocytes, and partial motor function decline ^[129]. NLY01 is in a phase II trial; the status is under recruitment which is developing by Neuraly, and they estimate to complete it by December 2022 (Table 1) (NCT04154072).